



PRESS RELEASE  
16 March 2026 15:00:00 CET

## Independent Stockholm3 screening study selected as Best Oncology Abstract at EAU26

**An independent study evaluating the use of the Stockholm3 test within Sweden's organized prostate cancer testing (OPT) program has been awarded Best Oncology Abstract at the Annual European Association of Urology (EAU) Congress, one of the world's largest scientific meetings in urology, in London.**

The study was conducted by investigators within the OPT program, Sweden's national initiative designed to evaluate organized prostate cancer screening strategies. The research assessed the impact of incorporating Stockholm3 as part of a risk-stratified screening pathway in a population-based program.

Results presented at EAU demonstrated that integrating Stockholm3 into the screening pathway substantially reduced the number of men referred for MRI and biopsy, highlighting the potential of risk-adapted screening approaches to improve efficiency while maintaining detection of clinically significant prostate cancer.[1]

"Organized prostate cancer screening programs must balance early detection with the burden of unnecessary diagnostic procedures," said Ugo Falagario, Urologist and Assistant Professor at the Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy and first author of the study.

"Our findings demonstrate that it is possible to integrate an advanced blood-based risk test into an organized prostate cancer testing program while reducing the burden on healthcare resources. This is important both for patients and for the sustainability of healthcare systems," says Anna Lantz, Associate Professor at the Department of Molecular Medicine and Surgery and consultant urologist at Karolinska University Hospital, who led the study.

The study (N=13,901) evaluated outcomes among men participating in the OPT screening program, representing a real-world implementation of organized prostate cancer testing. The findings add to the growing body of evidence supporting risk-stratified prostate cancer screening strategies that combine biomarkers with imaging and clinical assessment.

"This recognition at EAU underscores the growing interest in more sophisticated screening strategies beyond PSA alone," said Martin Steinberg, CEO of A3P Biomedical, developer of Stockholm3. "Independent studies such as this provide important validation of how biomarker-driven approaches can improve prostate cancer screening programs."

A3P Biomedical AB (publ)



[1] Falagario U.G, Akre O., Carlsson S. et al. Stockholm3 test performance for reducing MRI in Organised Prostate Cancer Testing (OPT). EAU26 - 41st Annual European Association of Urology (EAU) Congress; March 13-16, London, UK.

**For additional information, please contact:**

---

Cecilia Edström, acting CFO  
Telephone: +46 72 226 23 28  
Email: [cecilia.edstrom@a3p.com](mailto:cecilia.edstrom@a3p.com)

**About A3P Biomedical**

---

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P's main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit [www.a3p.com](http://www.a3p.com)

**About Stockholm3**

---

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit [www.stockholm3.com/](http://www.stockholm3.com/)

---

A3P Biomedical AB (publ)



## About prostate cancer

---

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

## Attachments

---

[Independent Stockholm3 screening study selected as Best Oncology Abstract at EAU26](#)